Europe — EMA
Neupogen Singleject (Filgrastim)
Filgrastim, the active ingredient in Neupogen Singleject, is a granulocyte colony‑stimulating factor presented as a solution for injection for intravenous or subcutaneous use.
Request sourcing
What is Filgrastim?
Filgrastim, the active ingredient in Neupogen Singleject, is a granulocyte colony‑stimulating factor presented as a solution for injection for intravenous or subcutaneous use. It stimulates neutrophil production and is used to treat neutropenia in patients receiving myelosuppressive chemotherapy, severe chronic neutropenia, and to mobilize progenitor cells for transplantation.
GNH USA supplies Neupogen Singleject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.
What is Filgrastim used for?
Neupogen Singleject (filgrastim) is used to manage conditions involving impaired neutrophil production.
- Neutropenia associated with myelosuppressive chemotherapy: reduces the duration of severe neutropenia and lowers infection risk. - Severe chronic neutropenia: increases absolute neutrophil count and improves clinical outcomes. - Bone marrow transplantation: enhances neutrophil recovery after transplant. - Peripheral blood progenitor cell mobilization: facilitates collection of CD34+ cells for autologous transplantation.
What are the side effects of Filgrastim?
Filgrastim may cause a range of adverse reactions, varying from mild to serious.
Common Side Effects: - Bone pain: discomfort in the limbs or back. - Injection site reactions: redness, swelling, or tenderness. - Fever: low‑grade temperature elevation. - Fatigue: feeling unusually tired. - Headache: mild to moderate head discomfort. - Nausea: occasional upset stomach.
Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and shock. - Acute respiratory distress syndrome: severe breathing difficulty. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Capillary leak syndrome: low blood pressure and edema. - Leukocytosis: excessively high white‑blood‑cell count. - Severe hypotension: sudden drop in blood pressure.
What precautions apply to Filgrastim?
Before using Neupogen Singleject, clinicians should consider several safety measures.
- Monitor blood counts: regular CBC to assess neutrophil response. - Assess splenomegaly: evaluate spleen size before and during therapy. - Use caution in sickle‑cell disease: increased risk of vaso‑occlusive
